Cellectar Biosciences, Inc. (CLRB)
Develops radioactive drugs targeting cancer cells while leaving healthy tissue alone.
$2.50+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-47.0%
The outlook
CLRB is trading near its 52-week low, well below its key moving averages, reflecting weak near-term momentum. Analyst coverage shows an average price target about 360% above the current price, though this wide gap suggests significant disagreement or limited analyst attention. The overall sentiment leans bearish despite the elevated target.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +360% vs current price
Analyst price target
~12-month · 4 analysts$11.50average target+360.0% vs now
Now $2.50
Low $10.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$20.0M
52-wk high
$6.52
52-wk low
$2.20
50-day avg
$2.70
200-day avg
$3.13
Trailing P/E
—